Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis
Frontiers in Pharmacology · 31.10.2025 · 16
DOI: 10.3389/fphar.2025.1652789 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.10.2025. Verfasst von Ying Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Chinese Medical University, Hangzhou, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Idiopathic membranous nephropathy (IMN) is a common cause of nephrotic syndrome in adults, with current immunosuppressive therapies often limited by incomplete efficacy, significant toxicity, and high cost. Extracts from Tripterygium wilfordii, particularly its glycosides (TWG), have emerged as a potential alternative with immunomodulatory properties.
Objectives
To evaluate the clinical efficacy and safety of TWG in the treatment of IMN.
Methods
We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases from inception to September 2025. Randomized controlled trials (RCTs) and observational studies comparing TWG with standard therapies were included. Risk ratios (RR) and standardized mean differences (SMD) were pooled using a random-effects model.
Results
This meta-analysis incorporated 20 studies (1,789 patients). TWG significantly improved the total response rate (RR = 1.27; 95% confidence interval (CI): 1.12–1.44), complete remission rate (RR = 1.81; 95% CI: 1.13–2.90), and reduced 24-h urinary protein (SMD = −2.09; 95% CI: 3.46 to −0.71) and recurrence risk (RR = 0.56; 95% CI: 0.37–0.86). However, the evidence was characterized by high heterogeneity (I 2 > 50% for most efficacy outcomes) and a high risk of bias in 17 of the 20 included studies. No significant difference was observed in serum albumin (SMD = 1.20; 95% CI: 0.25–2.64) or the overall incidence of inadequately reported adverse events (RR = 0.93; 95% CI: 0.65–1.34).
Conclusion
TWG may represent a beneficial therapeutic strategy for IMN, potentially improving remission rates and reducing proteinuria. However, the conclusiveness of these findings is constrained by the high risk of bias in the primary studies, substantial heterogeneity, and inadequate safety reporting. Future robust, multi-regional RCTs are required to definitively establish its efficacy and safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhejiang Chinese Medical University, Hangzhou, China.
- Zhejiang Chinese Medical University Affiliated Third Hospital, Hangzhou, China.
Zitieren
APA
Liu, Y., & Lu, K. (2025). Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1652789
Vancouver
Liu Y, Lu K. Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1652789
BibTeX
@article{Liu2025,
author = {Liu, Ying and Lu, Keda},
title = {Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1652789}
}
EUVIMED